Stockscreener 앱 받기
3.70
0.54%
-0.02
시장 영업 전:
3.62
-0.08
-2.16%
Adagene Inc Adr 주식(ADAG)의 최신 뉴스
Adagene (ADAG): WuXi PharmaTech and WuXi AppTec disclose 3.5% beneficial stake - Stock Titan
Adagene Inc. (Nasdaq: ADAG) boosts cash to US$127.9M and updates H1 2026 results - Stock Titan
Adagene’s Cancer Trial Results Expected in 1H 2027 - Stock Titan
Adagene (NASDAQ:ADAG) CEO Peter Luo Acquires 22,966 Shares - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Adagene (ADAG) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
Guggenheim reiterates Adagene stock Buy rating on competitor shift - Investing.com
ADAG Stock Price, Quote & Chart - ChartMill
Adagene (ADAG) Stifel 2026 Targeted Oncology Virtual Forum Summary - Quartr
Adagene Discloses Preliminary US$127.9 Million Cash Balance as of June 30, 2026 - The Globe and Mail
Adagene (ADAG) reports preliminary US$127.9M cash balance in June 2026 6-K - Stock Titan
ADAG - Finviz
Adagene, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:ADAG) - TradingView
Adagene (ADAG) upgraded to buy: Here's what you should know - MSN
Adagene (NASDAQ: ADAG) Schedule 13D/A details Luo group and trust stakes - Stock Titan
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Guggenheim raises Adagene stock price target on cancer drug data - Investing.com
Are medical stocks lagging Adagene (ADAG) this year? - MSN
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene spotlights ADG126 strategy as masked CTLA-4 trial advances in colorectal cancer - MSN
Adagene Inc. (ADAG) Presses Lower: Support Test in Sight After 1.88% DeclineLate Stage Breakouts - dars.gov.et
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer - sharewise.com
WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG) - Stock Titan
Adagene Inc. to Participate in Stifel Annual Virtual Oncology Event and Jefferies Global Healthcare Conference - Quiver Quantitative
Adagene to Participate in Two Upcoming Investor Conferences - marketscreener.com
Janus Henderson (ADAG) reports 6.67M ADRs, 10.1% stake (04/30/2026) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
Adagene announces pricing of $70M public offering of ADS - MSN
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene and Incyte Partner to Develop Colorectal Cancer Therapy - HarianBasis.co
Qinghai Zhao Net Worth (2026) - GuruFocus
Adagene reports trial data for cancer drug muzastotug combos By Investing.com - Investing.com South Africa
Adagene reports trial data for cancer drug muzastotug combos - Investing.com
Experimental Adagene drug lifts liver cancer response to 66.7% - Stock Titan
Adagene (NASDAQ: ADAG) shows strong AACR 2026 data for muzastotug combo therapies - Stock Titan
Adagene Presents Two Posters at AACR 2026 with New Data - GlobeNewswire
Adagene Looks Attractive With ADG126 And Validating Partnerships (NASDAQ:ADAG) - Seeking Alpha
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Adagene appoints Peter Lebowitz to advisory board - Investing.com
Adagene appoints Peter Lebowitz to advisory board By Investing.com - Investing.com India
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - Bitget
Analysts Offer Predictions for Adagene FY2026 Earnings - MarketBeat
H.C. Wainwright reiterates Adagene stock rating on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Adagene stock rating on trial data - Investing.com
Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price - MarketBeat
Guggenheim raises Adagene stock price target on cancer drug data By Investing.com - Investing.com South Africa
0.52%
0.07%
자본화:
|
볼륨(24시간):